Meridian Bioscience, Inc. (VIVO) Tops Q2 EPS by 2c; Reaffirms Outlook

Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $47.4 million versus the consensus estimate of $44.82 million.

Meridian Bioscience, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
• MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs